Loading news...
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) was the recipient of a significant growth in short interest in December. As of December 31st, there was short interest totaling 8,244,450 shares, a growth of 20.1% from the December 15th total of 6,865,432 shares. Based on an average trading volume of 672,703 shares, the days-to-cover ratio
MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech stocks, and beaten-down REITs that offer solid income and turnaround potential. Part 3 of this series includes Ceragon Networks, Celldex Therapeutics, Constellation Energy, Coppernico Metals, Costco, and Dynex Capital, among others.
Multiple Senior Vice Presidents of this biotech company recently engaged in transactions that involved thousands of shares. What does this mean for the stock as it continues its long journey to regain price value?
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven research firms that are covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report)'s share price shot up 4.1% during mid-day trading on Wednesday. The stock traded as high as $27.46 and last traded at $27.52. 215,440 shares were traded during mid-day trading, a decline of 78% from the average session volume of 981,881 shares. The stock had previously closed
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) shares passed above its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $24.38 and traded as high as $26.60. Celldex Therapeutics shares last traded at $26.03, with a volume of 491,410 shares changing hands. Wall
Corient Private Wealth LLC acquired a new position in shares of Celldex Therapeutics, Inc. (NASDAQ: CLDX) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 201,717 shares of the biopharmaceutical company's stock, valued at approximately $4,105,000. Corient Private Wealth LLC owned
Celldex Therapeutics, Inc. (NASDAQ: CLDX - Get Free Report) has received a consensus rating of "Moderate Buy" from the eleven brokerages that are presently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has issued
HAMPTON, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the initiation of its global Phase 3 trial (EMBARQ-ColdU and SD) designed to establish the efficacy and safety of barzolvolimab in adult patients with cold urticaria (ColdU) and symptomatic dermographism (SD) who remain symptomatic despite H1 antihistamine treatment. ColdU and SD are characterized by the occurrence of hives or wheals that have an attributable trigger associated with them—exposure to cold temperatures in ColdU and scratching/rubbing of the skin in SD. Mast cell activation is known to be a critical driver in ColdU and SD. Barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival.
Fisher Asset Management LLC lowered its position in Celldex Therapeutics, Inc. (NASDAQ: CLDX) by 5.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 822,208 shares of the biopharmaceutical company's stock after selling 49,420 shares during the period. Fisher Asset
American Century Companies Inc. grew its position in Celldex Therapeutics, Inc. (NASDAQ: CLDX) by 24.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 779,985 shares of the biopharmaceutical company's stock after acquiring an additional 154,664 shares during the
HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare executive with 30 years of strategic, commercial launch and operating P&L leadership across the biopharmaceutical, medical device and consumer health technology sectors. Ms. Lawver succeeds Richard Wright, who will retire from Celldex following more than a decade of dedicated leadership and service.
HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences:
Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU
Celldex Therapeutics, Inc. (NASDAQ:CLDX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 3:20 PM EDT Company Participants Anthony S. Marucci - Founder, President, CEO & Director Tibor Keler - Founder, Chief Scientific Officer & Executive VP Diane Young - Senior VP & Chief Medical Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst Welcome, everyone, to this session of the Morgan Stanley Global Healthcare Conference.
HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanley 23rd Annual Global Healthcare Conference at 3:20 pm ET. A live webcast of the presentation will be available on the "Events & Presentations” page of the "Investors" section of the Celldex website. A replay will be available for 90 days following the event.
Celldex Therapeutics, Inc.'s barzolvolimab failed to improve symptoms in eosinophilic esophagitis, but this setback doesn't impact its promising ongoing urticaria programs. Phase 3 trials for chronic spontaneous urticaria are underway, with additional studies for chronic inducible urticaria set to begin soon in 2nd half of 2025. The global urticaria market size is projected to reach $11.4 billion by 2032.
On Tuesday, Celldex Therapeutics, Inc. CLDX released topline results from its ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.
HAMPTON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported topline results from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus. Identifying the key drivers of EoE has challenged the field and research has suggested that mast cells could play an important role in the disease pathogenesis. Celldex designed this study to determine if barzolvolimab could deplete mucosal (intraepithelial) mast cells and, in turn, improve clinical outcomes in EoE. The primary endpoint of the study, absolute change from baseline to Week 12 in peak esophageal intraepithelial mast cell count was met, but the profound mast cell depletion observed did not result in improvement in EoE symptoms or endoscopic assessment of disease activity compared to placebo. Consistent with previously reported studies, barzolvolimab demonstrated a favorable safety and tolerability profile. Based on these results, Celldex will not advance development in EoE. The results do support future development with KIT- or SCF-targeted therapies in other GI indications where mucosal mast cells are believed to play an important role.
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.85 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to a loss of $0.54 per share a year ago.